A Louisiana jury has awarded $10 million in a mesothelioma case linked to decades of talc exposure, assigning Johnson & Johnson over $1.2 million of the liability while finding its talc products unreasonably dangerous and inadequately labeled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson, which is also pursuing a proposed $5.5 billion settlement to resolve about 76,000 ovarian cancer claims. The company's investment narrative projects $120.5 billion in revenue and $28.6 billion in earnings by 2029, requiring 7.2% yearly revenue growth and a $7.6 billion earnings increase from $21 billion today. Analysts note that repeated adverse outcomes could affect how investors view cash flow resilience and the value of future product launches, even as the company's expanding oncology and immunology portfolio continues to post record quarterly sales.
Johnson & JohnsonLouisiana jury verdict finds talc products unreasonably dangerous and inadequately labeled, adding to litigation losses.
